摘要
目的对前列地尔联合贝那普利治疗糖尿病肾病蛋白尿临床效果进行分析。方法 82例糖尿病肾病患者,随机分为研究组和对照组,各41例。对照组采取贝那普利治疗,研究组在对照组基础上联合前列地尔治疗,对比两组患者治疗前后24 h尿蛋白定量、24 h尿微量白蛋白排泄率及治疗效果。结果治疗前,两组患者24 h尿蛋白定量及24 h尿微量白蛋白排泄率比较差异无统计学意义(P>0.05);治疗后,两组患者24 h尿蛋白定量及24 h尿微量白蛋白排泄率均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05)。研究组总有效率(97.56%)高于对照组(85.37%),差异有统计学意义(P<0.05)。结论前列地尔联合贝那普利能有效控制糖尿病肾病患者病情,可降低尿微量白蛋白排泄率。
Objective To analyze the clinical effect of alprostadil combined with benazepril on proteinuria in patients with diabetic nephropathy.Methods A total of82patients with diabetic nephropathy were randomly divided into research group and control group,with41cases in each group.The control group was treated with benazepril,and the research group was treated with alprostadil on the basis of the control group.Comparison were made on24h urinary protein quantitation,24h urinary albumin excretion rate before and after treatment and treatment effect between two groups.Results Before treatment,both groups had no statistically significant difference in24h urinary protein quantitation,24h urinary albumin excretion rate(P>0.05).After treatment,both groups had lower24h urinary protein quantitation,24h urinary albumin excretion rate than before treatment,and the research group was lower than the control group.Their difference was statistically significant(P<0.05).The research group had higher total effective rate(97.56%)than the control group(85.37%),and the difference was statistically significant(P<0.05).Conclusion Combination of alprostadil and benazepril can effectively control the condition of patients with diabetic nephropathy,and reduce the excretion rate of urinary albumin.
作者
沈宁阳
SHEN Ning-yang(Liaoyang Central Hospital, Liaoyang 111000, China)
出处
《中国现代药物应用》
2017年第23期88-89,共2页
Chinese Journal of Modern Drug Application
